

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-222

CHEMISTRY REVIEW(S)

DIVISION OF ANTI-INFECTIVE DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

##3

NDA #: 21-222 **CHEM.REVIEW #:** 1 **REVIEW DATE:** 15-Sept-2000

<u>SUBMISSION/TYPE</u>	<u>DOCUMENT DATE</u>	<u>CDER DATE</u>	<u>ASSIGNED DATE</u>
------------------------	----------------------	------------------	----------------------

ORIGINAL:yes	12/28/99	12/29/99	1/4/2000
AMENDMENT BC:	06/13/00	06/14/00	06/15/2000
Amendment BC: (stability update)	7/12/00	7/13/00	7/20/00

NAME & ADDRESS OF APPLICANT:

Tap Holdings Inc.
2355 Waukegan Road
Deerfield.IL 60015

DRUG PRODUCT NAME

Proprietary:SPECTRACEF
Nonproprietary/USAN:Cefditoren pivoxil
Code Names/#'s:MF1207,A-CDTR,RCF,CDTR-Pl
Chemical Type/:Antibiotic
Therapeutic Class: IS

ANDA Suitability Petition/DESI/Patent Status:

N/A [if applicable]

PHARMACOLOGICAL CATEGORY/INDICATION:Antibiotic

For the treatment of pharyngitis/tonsillitis;Acute exacerbations of chronic bronchitis.

DOSAGE FORM: Tablets**STRENGTHS:** 200mg**ROUTE OF ADMINISTRATION:** Oral**DISPENSED:** Rx OTC**CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA.**

1. Name and chemical structure

1.1. Generic name

Cefditoren pivoxil


1.2. Chemical name

(-)-(6R, 7R)-2, 2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

1.3. Abbreviation

CDTR-PI

1.4. Structural formula



1.5. Molecular formula

$C_{25}H_{28}N_6O_7S_3$

1.6. Molecular weight

620.73

SUPPORTING DOCUMENTS:



RELATED DOCUMENTS (if applicable):

None

CONSULTS:

1. METHOD VALIDATION: ADEQUATE

Both the Puerto Rico District Laboratory and the Philadelphia District Laboratory have found the methods acceptable for regulatory purposes.

2. INSPECTION: PENDING

All the facilities were found to be ACCEPTABLE as of July 13, 2000 except the following which was added by the firm recently by an amendment as an alternate packaging site:




:

The firm claims that the above facility had a satisfactory GMP inspection on January 7, 2000. However, Dr. David Katague, in Dr. Shetty, s absence (vacation) had requested to EES Question on July 20, 2000 to add the above facility to EER.


3. PROPRIETARY NAME: ADEQUATE

The name was found to be acceptable.

REMARKS/COMMENTS:



CONCLUSIONS & RECOMMENDATIONS: APPROVABLE
Recommend approval; EER is ACCEPTABLE. See attached.



B.V.Shetty, Review Chemist

cc:
Orig. NDA 21-222
HFD-520/Division File
HFD-520/B.V.Shetty/date
HFD-520/J.Alexander
HFD-520/K.Seethaler
HFD-520/J.Unowsky
HFD-520/G.Hills
HFD-520/F.Pelsor
HFD-830/C.Chen
HFD-520/D.Katague

DIVISION OF ANTI-INFECTIVE DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA #: 21-222 **CHEM.REVIEW #:** 2 **REVIEW DATE:** 10/17/2000

SUBMISSION/TYPE DOCUMENT DATE CDER DATE ASSIGNED DATE

Amendment (BC) 10/5/2000 10/6/2000 10/13/2000
(Response to IR letter tele-faxed to applicant on September 20, 2000)

NAME & ADDRESS OF APPLICANT:

Tap Holdings Inc.
2355 Waukegan Road
Deerfield, .IL 60015

DRUG PRODUCT NAME

Proprietary: SPECTRACEF
Nonproprietary/USAN: Cefditoren pivoxil
Code Names/#'s: MF1207, A-CDTR, RCF, CDTR-Pl
: Chemical Type/: Antibiotic
Therapeutic Class: IS

ANDA Suitability Petition/DESI/Patent Status:

N/A [if applicable]

PHARMACOLOGICAL CATEGORY/INDICATION: Antibiotic

For the treatment of pharyngitis/tonsillitis; Acute exacerbations of chronic bronchitis.

DOSAGE FORM: Tablets

STRENGTHS: 200mg

ROUTE OF ADMINISTRATION: Oral

DISPENSED: X Rx ___ OTC

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA.

1. Name and chemical structure

1.1. Generic name

Cefditoren pivoxil


1.2. Chemical name

(-)-(6R, 7R)-2, 2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

1.3. Abbreviation

CDTR-PI

1.4. Structural formula




1.5. Molecular formula

C₂₅H₂₈N₆O₇S₃

1.6. Molecular weight

620.73

SUPPORTING DOCUMENTS:



RELATED DOCUMENTS (if applicable):

NONE

CONSULTS:

NONE

REMARKS/COMMENTS:

The current submission is the firm's response to the IR letter tele-faxed on Septmeber 20, 2000, as outlined in Chemist Review #1 dated September 15, 2000.

CONCLUSIONS & RECOMMENDATIONS:

APPROVAL

The applicant has satisfactorily has answered all the deficiencies stated in chemist review #1 dated September 15,2000. NDA 21-222 is recommended for APPROVAL from CMC point of view, Method Validations, locality inspections and trade name have all been found to be ACCEPTABLE.

IS/

10/24/00

B.V.Shetty, Review Chemist

DIVISION OF ANTI-INFECTIVE DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA #: 21-222 CHEM.REVIEW #: 3 REVIEW DATE: 6/22/01

<u>SUBMISSION/TYPE</u>	<u>DOCUMENT DATE</u>	<u>CDER DATE</u>	<u>ASSIGNED DATE</u>
ORIGINAL:yes	12/28/99	12/29/99	1/4/2000
Amendment BC: (stability update)	7/12/00	7/13/00	7/20/00

NAME & ADDRESS OF APPLICANT:

Tap Holdings Inc.
2355 Waukegan Road
Deerfield.IL 60015

DRUG PRODUCT NAME

Proprietary:SPECTRACEF
Nonproprietary/USAN:Cefditoren pivoxil
Code Names/ #'s:MF1207,A-CDTR,RCF,CDTR-P1
Chemical Type:Antibiotic
Therapeutic Class: IS

ANDA Suitability Petition/DESI/Patent Status:

N/A [if applicable]

PHARMACOLOGICAL CATEGORY/INDICATION:Antibiotic

For the treatment of pharyngitis/tonsillitis;Acute
exacerbations of chronic bronchitis.

DOSAGE FORM: Tablets

STRENGTHS: 200mg

ROUTE OF ADMINISTRATION: Oral

DISPENSED: Rx OTC

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA.

1. Name and chemical structure

1.1. Generic name

Cefditoren pivoxil


1.2. Chemical name

(-)-(6R, 7R)-2, 2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

1.3. Abbreviation

CDTR-PI

1.4. Structural formula



1.5. Molecular formula

$C_{25}H_{28}N_6O_7S_3$

1.6. Molecular weight

620.73

SUPPORTING DOCUMENTS:



RELATED DOCUMENTS (if applicable):

None

CONSULTS:

1. METHOD VALIDATION:
ADEQUATE


Both the Puerto Rico District Laboratory and the Philadelphia District Laboratory have found the methods acceptable for regulatory purposes.

2. INSPECTION:
PENDING

All the facilities were found to be ACCEPTABLE as of July 13, 2000 except the following which was added by the firm recently by an amendment as an alternate packaging site:



The firm claims that the above facility had a satisfactory GMP inspection on January 7, 2000. However, Dr. David Katague, in

Dr. Shetty, s absence (vacation) had requested to EES Question on July 20, 2000 to add the above facility to EER. 

3. PROPRIETARY NAME:
ADEQUATE

The name was found to be acceptable.

REMARKS/COMMENTS:

[Redacted]

CONCLUSIONS & RECOMMENDATIONS:

APPROVABLE

Recommend to approve this NDA.;EER is ACCEPTABLE. See attached.

[Redacted]

B.V.Shetty, Review Chemist

cc:
Orig. NDA 21-222
HFD-520/Division File
HFD-520/B.V.Shetty/date
HFD-520/J.Alexander
HFD-520/K.Seethaler
HFD-520/J.Unowsky
HFD-520/G.Hills
HFD-520/F.Pelsor
HFD-830/C.Chen